Use of metformin (siofor®) in patients with gout and insulin resistance (pilot 6-month results)

Terapevticheskii Arkhiv

Volumn 77, Issue 12, 2005, Pages 44-48

  Barskova, V G ^a   Eliseev, M S ^a   Nasonov, E L ^a   Volkov, A V ^a   Tsapina, T N ^a   Zilov, A V ^a   Yakunina, I A ^a   Ilinykh, E V ^a   Kudaeva, F M ^a  

^a NONE

Author keywords

Gout; Insulin resistance; Metformin; Uric acid

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; FEMALE; FOLLOW-UP STUDIES; GOUT; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URIC ACID;

EID: 33144467290     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Engelhardt H. T., Wagner E. L. Gout, diabetes mellitus and obesity, a poorly recognized syndrome. South. Med. J. 1950; 43: 51-53.
2. Berkowitz D. Gout, hyperlipidemia and diabetes interrelationships. J. A. M. A. 1966; 197: 77-80.
3. Takahashi S., Moriwaki Y., Tsutsumi Z. et al. Increased visceral fat accumulation further aggravates the risk of insulin resistance in gout. Metabolism 2001; 50 (4): 393-398.
4. Dessein P. H., Stanwix A. E., Shipton E. A. et al. Dislipidemia and insulin resistance in gout: sufficiently common to be considered in the evaluation and management of every patient. III. In: African League Against Rheumatism (AFLAR) conference. Cape Town, South Africa, September 1999. Cape Town: Ukenza; 1999: 1-30.
5. De Fronzo R. A., Ferranninni E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
6. Assmann G., Cullen P., Schulte H. The Münster Heart Study (PROCAM): results of follow-up at 8 years. Eur. Heart J. 1998; 19 (suppl. A): A2-A11.
7. Eckel R. H., Krauss R. M. for the AHA Nutrition Committee. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 1998; 97: 2099-2100.
8. Facchini F., Ida Chen Y. D., Hollenbeck C. B., Reaven G. M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration. J. A. M. A. 1991; 266: 3008-3011.
9. Muscelli E., Natali A., Bianchi S. et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am. J. Hypertens. 1996; 9: 746-752.
10. Ter Maaten J. C., Voorburg A., Heine R. J. et al. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin. Sci. (Lond.) 1997; 92: 51-58.
11. Fam A. G. Gout, diet, and the insulin resistance syndrome. J. Rheumatol. 2002; 29 (7): 1350-1355.
12. Kirpichnikov D., McFarlan S. I., Sowers J. R. Metformin: an update. Ann. Intern. Med. 2002; 137: 25-33.
13. Palumbo P. J. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J. Diabetes Complicat. 1998; 12: 110-119.
14. Tinahones J. F., Perez-Lindon G., C-Soriguer F. J. et al. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J. Clin. Endocrinol. Metab. 1997; 82: 1188-1191.
15. Wallace S. L., Robinson H., Masi A. T. et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthr. and Rheum, 1977; 20: 895-900.
16. Borona E., Targer G., Alberiche M. et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000; 23: 57-63.
17. Masanori E., Yoshiki N., Kiyoshi M. et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999; 22: 818-822.
18. Haffner S. M., Gonzalez C., Miettinen H. et al. A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138-1141.
19. Alberty K. G., Zimmet P. Z. for the WHO Consultation Group. Definition, diagnosis and classification of diabetes mellitus and its complication. Part I: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 1998; 15: 539-553.
20. Snaith M. Gout and alconol. J. Rheumatol. 2004; 43: 1208-1209.
21. Gul S., Advardar Y., Tas G., Tuncel P. Turk Psikiyatri Derg. Spring; 2005; 16 (1): 3-12.
22. World Health Organization (WHO). Prevention and management of the global epidemic of obesity. Report of the WHO consultation on obesity (Geneva, 3-5 June, 1997). Geneva: WHO.
23. Expert panel on detection, evalution and treatment of high blood cholesterol in adults. Executive summary of the Third report of National Ch. E. Prog. Expert Panel on Detection, Evaluation and Treatment of high Blood Chol. in adults (adult treatment panel III). J. A. M. A. 2001; 285: 2486-2497.
24. Lean M. E. Clinical handbook of weight management.: Martin Dunitz; 1998. 113.
25. Nagi D. K., Yudkin J. S. Effect of metformin of insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-629.
26. Chan J. C., Tomlinson B., Critchley J. A. et al. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993; 16: 1035-1038.
27. Zimmet P., Collier G. Clinical efficacy of metformin against insulin resistance parameters. Drugs 1999; 58 (suppl. 1): 21-28.
28. Reaven G. M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
29. Haffner S. M., Stern M., Hazuda H. P. et al. Cardiovascular risk factors in confimed prediabetic individuals. J. A. M. A. 1990; 263: 2893-2898.
30. Meigs J. B., Mittleman M. A., Nathan D. M. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. J. A. M. A. 2000; 283: 221-228.
31. Gin H., Messerchmitt C., Brottier E., Aubertin J. Metformin improved insulin resistance in type I insulin-dependent diabetic patients. Metabolism 1985; 34: 923-925.
32. Nosacini R., Avogaro A., Trevisan R. et al. Effect of metformin on insulinstimulared glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987; 10: 62-67.
33. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
34. Johnson J., Simpson S., Majumdar S., Toth E. Decreased mortality associated with the use of metformin compared with sulphonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
35. Shoji A., Yamanaka H., Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthr. and Rheum. 2004; 51 (3): 321-325.